HMGCR and cardiovascular disorder: Statins, originally designed as inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-co-enzyme A reductase (HMG-CoA reductase) of the cholesterol biosynthesis pathway [9,10], have been widely used for lipid-lowering purposes with a good safety profile in cardiovascular diseases.